Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;24(4):143-9.
doi: 10.1016/j.sjopt.2010.06.003. Epub 2010 Jun 30.

Current concepts in intravitreal drug therapy for diabetic retinopathy

Anant Pai  1 , Maha M El Shafei, Osman A Z Mohammed, Mustafa Al Hashimi
Affiliations

Current concepts in intravitreal drug therapy for diabetic retinopathy

Anant Pai et al. Saudi J Ophthalmol. 2010 Oct.

Abstract

Diabetic retinopathy (DR) is a major cause of preventable blindness in the developed countries. Despite the advances in understanding and management of DR, it remains a challenging condition to manage. The standard of care for patients with DR include strict metabolic control of hyperglycemia, blood pressure control, normalization of serum lipids, prompt retinal laser photocoagulation and vitrectomy. For patients who respond poorly and who progressively lose vision in spite of the standard of care, intravitreal administration of steroids or/and anti-vascular endothelial growth factor (anti-VEGF) drugs appear to be a promising second-line of therapy. This review discusses the current concepts and the role of these novel therapeutic approaches in the management of DR.

Keywords: Anti-VEGF drugs; Diabetic retinopathy; Intravitreal steroids.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classification of diabetic retinopathy.
See this image and copyright information in PMC

References

    1. Abdulla Walid, Fazwi Amani. Anti-VEGF therapy in proliferative diabetic retinopathy. Int. Ophthalmol. Clin. 2009;49:95–107. - PubMed
    1. Adamis A.P., Altaweel M., Bressler N.M. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113(1):23–28. - PubMed
    1. Aiello L.P. Angiogenic pathways in diabetic retinopathy. N. Engl. J. Med. 2005;353:839–841. - PubMed
    1. Chen E., Park C.H. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699–700. - PubMed
    1. Chew E.Y., Klein M.L., Ferris F.L., III Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Ophthalmol. 1996;114:1079–1084. - PubMed

LinkOut - more resources